{"protocolSection":{"identificationModule":{"nctId":"NCT06482346","orgStudyIdInfo":{"id":"MT-3534-Z-101"},"organization":{"fullName":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"},"briefTitle":"MT-3534 Clinical Pharmacology Study in Healthy Adult Male Volunteers","officialTitle":"MT-3534 Clinical Pharmacology Study in Healthy Adult Male Volunteers (SAD Study)"},"statusModule":{"statusVerifiedDate":"2024-05","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-25","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is planned to investigate the safety, tolerability, and pharmacokinetics when a single intravenous dose of MT-3534 or a placebo is given to healthy adult male volunteers."},"conditionsModule":{"conditions":["Healthy Adult Male Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":56,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"MT-3534","type":"EXPERIMENTAL","description":"Intravenous (IV)","interventionNames":["Biological: MT-3534"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Intravenous (IV)","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"MT-3534","description":"Solution for infusion; Intravenous (IV)","armGroupLabels":["MT-3534"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Solution for infusion; Intravenous (IV)","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of subjects with adverse events","timeFrame":"up to Day 85"},{"measure":"Number of subjects with adverse reactions","timeFrame":"up to Day 85"},{"measure":"Serum concentrations of MT-3534","timeFrame":"up to Day 85"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy adult male volunteer\n* Japanese (Part A) or White (Part B)\n* Subjects with age of 18 to 55 years old at informed consent\n* Subjects with a full understanding of the nature of this study and consented in writing to participate in the study\n\nExclusion Criteria:\n\nAdditional screening criteria check may apply for qualification:\n\n* Subjects with a current or prior disease history of cardiac, hepatic, renal, gastrointestinal, respiratory, neuropsychiatric, hematopoietic, endocrine systems, etc. whom the investigator has judged to be unfit for study participation\n* Subjects with a history of drug or food allergies\n* Subjects with a history of hypersensitivity to any of the ingredients of MT-3534\n* Subjects whose BMI is less than 18.5 kg/m\\^2 or exceeds 25.0 kg/m\\^2, or subjects weighing less than 50.0 kg or exceeds 80.0 kg at the time of screening or Day -1 tests (Part A). Subjects whose BMI is less than 18.5 kg/m\\^2 or exceeds 30.0 kg/m\\^2, or subjects weighing less than 50.0 kg or exceeds 100.0 kg at the time of screening or Day -1 tests (Part B). (For BMI, values rounded to the first decimal place will be used.)\n* Subjects who have donated blood or from whom blood samples have been collected in a total amount of 400 mL or more in the 12 weeks, 200 mL or more in the 4 weeks, or 800 mL or more in the 52 weeks prior to informed consent\n* Subjects who have donated blood platelets or from whom blood samples have been collected in the 2 weeks prior to informed consent\n* Subjects with a current or prior history of dependence on drugs, alcohol, etc\n* Subjects with a history of cancer\n* Subjects who receive a live attenuated vaccine within 4 weeks before the start of investigational product administration\n* Subjects with a positive result for serological test for syphilis, Hepatitis C virus (HCV) antibody, or HIV antigen/antibody at screening\n* Subjects with a positive result for Hepatitis B virus surface (HBs) antigen, Hepatitis B virus core (HBc) antibody and HBs antibody at screening (Subjects with a negative for HBs antigen plus a positive for HBs antibody plus a negative for HBc antibody and who have obvious history of vaccination are eligible to enroll)\n* Subjects with a history of recurrent infections such as Herpes simplex or Herpes zoster\n* Subjects with a positive result for polymerase chain reaction (PCR) test for COVID-19 at Day -1 test\n* Subjects who do not agree to contraception from the date of informed consent until 12 weeks after the end of the administration of the investigational product\n* Subjects who have participated in other clinical studies and received other investigational products within 12 weeks before informed consent\n* Subjects who have used any drug other than the investigational product in the period within the 7 days before the start of investigational product administration or 5 times the half-life of the drug, whichever is longer\n* Subjects judged by the investigator (or subinvestigator) to be ineligible for the study for any other reason","healthyVolunteers":true,"sex":"MALE","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Trials Information Desk","role":"CONTACT","phone":"please email:","email":"cti-inq-ml@ml.mt-pharma.co.jp"}],"overallOfficials":[{"name":"General Manager","affiliation":"Mitsubishi Tanabe Pharma Corporation","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clinical Research Hospital Tokyo","city":"Shinjuku-ku","state":"Tokyo","zip":"160-0004","country":"Japan","geoPoint":{"lat":35.2946,"lon":139.57059}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"interventionBrowseModule":{"browseLeaves":[{"id":"M21860","name":"Pharmaceutical Solutions","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}